Becker's Healthcare January 22, 2025
Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.
The approval follows a priority review and is based on a clinical trial showing the drug alone led to significant improvement in depressive symptoms compared to placebo, with effects observable as early as 24 hours after being taken, according to a Jan. 21 news release from the drugmaker.
The trial demonstrated that Spravato outperformed the placebo on the Montgomery-Asberg...
Today's Sponsors
Today's Sponsor